Source: UNIV OF CONNECTICUT submitted to NRP
EVALUATING A SELF-BOOSTING VACCINE DELIVERY PLATFORM USING AD5-FMD
Sponsoring Institution
Agricultural Research Service/USDA
Project Status
ACTIVE
Funding Source
Reporting Frequency
Annual
Accession No.
0446668
Grant No.
(N/A)
Cumulative Award Amt.
(N/A)
Proposal No.
(N/A)
Multistate No.
(N/A)
Project Start Date
Aug 1, 2024
Project End Date
Jul 31, 2025
Grant Year
(N/A)
Program Code
[(N/A)]- (N/A)
Recipient Organization
UNIV OF CONNECTICUT
438 WHITNEY RD EXTENSION UNIT 1133
STORRS,CT 06269
Performing Department
(N/A)
Non Technical Summary
(N/A)
Animal Health Component
50%
Research Effort Categories
Basic
30%
Applied
50%
Developmental
20%
Classification

Knowledge Area (KA)Subject of Investigation (SOI)Field of Science (FOS)Percent
3110830104020%
3113310109040%
3113510110140%
Goals / Objectives
Previous research on the stability of Adenovirus type 5 (Ad5)-vectored expression systems (i.e., Ad5-Gluciferase) using a specific formulation resulted in stable luminescent signal both in vitro and in vivo. The objective of this collaborative effort is to conduct an in vivo proof-of-concept study to evaluate the efficacy of a self-boosting microneedle formulation using the Ad5-Foot and Mouth Disease (FMD) vectored expression system. Additionally, this study aims to evaluate the immunological efficiency of this novel delivery system.
Project Methods
1. Fabricating and characterizing the simple version of the Ad5-FMD vaccine microneedle formulation with immediate release, sufficient vaccine dose, mechanical strength and stability in vitro. 2. Characterizing the immunogenic efficiency and safety of the simple version microneedles in vivo.